Black Diamond Therapeutics, Inc. (BDTX) vs Genelux Corporation (GNLX)

Black Diamond Therapeutics, Inc. and Genelux Corporation are both Biotechnology companies. Black Diamond Therapeutics, Inc. and Genelux Corporation are of similar size ($110.0M and $108.6M). Across the 9 metrics below, Black Diamond Therapeutics, Inc. leads on 7 and Genelux Corporation on 2.

Valuation

Metric BDTX GNLX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 9.91 11.47
P/B 1.13 6.92 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.04 n/m 0.74
EV/Sales n/m 8.37 10.73
Earnings yield (39.68%) (34.68%) (28.84%)
Free cash flow yield (30.26%) (25.73%) (23.03%)

Profitability

Metric BDTX GNLX Biotechnology median
Gross margin 0.00% (3.42%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (37.21%) (177.93%) (57.72%)
Return on assets (29.21%) (121.80%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDTX GNLX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 130.71% 9.47% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDTX GNLX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.28 2.39 4.73
Net debt to EBITDA (10.01) 0.44 0.96

Dividend

Metric BDTX GNLX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric BDTX GNLX Biotechnology median
Market cap 108.59m 109.95m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack